Opinion

Drug companies should keep a goal of effective communications as the priority in medical publications

FDA struggles with the new world of social media

New technologies are creating a powerful link between patients and healthcare providers. This Connected Health World has implications for pharmaceutical business practices

Aggressive cost competition and the continuing growth of generic substitution will separate retailers’ interests from manufacturers’

The desire to compare drugs’ efficacy is shifting from a purely medical decision to a financial one

Under the theme of personalized medicine, in vitro diagnostics will play an increasingly important role in new drug entries and new therapies

Better internal collaboration within companies is critical to improving the vital physician-rep relationship

The most basic impulse behind CER is the desire to control healthcare costs. The implications for the biopharma industry could be significant

Are you prepared?

Preventable medical and medication errors should figure more prominently in the current debate on healthcare reform

Private and public sectors can collaborate to achieve meaningful reform

More so than other classes of drugs, making choices about drugs for mental health conditions require everyone around the patient to be well informed

The current economic downturn may fuel the creation of new, more sustainable business models

Could proposed legislation undercut the promise of targeted therapies?

Claims of the death of the pharma sales rep occupation have been greatly exaggerated

Bipartisan group of senators sponsor a revived drug-importation bill

The studio model: how film industry practices can boost pharmaceutical creativity

FDA’s management of drug and device safety enters GAO’s biennial watch list